NDUFA4L2 regulates the progression and chemotherapy sensitivity of HNSCC by inhibiting PANoptosis - PubMed
4 days ago
- #Chemotherapy resistance
- #PANoptosis
- #HNSCC
- NDUFA4L2 regulates progression and chemotherapy sensitivity in HNSCC by inhibiting PANoptosis.
- Elevated NDUFA4L2 is linked to poor survival and low chemotherapy sensitivity in HNSCC patients.
- NDUFA4L2 knockout combined with cisplatin suppresses glycolysis, inhibits AIM2 inflammasome, and triggers PANoptosis.
- NDUFA4L2 serves as a prognostic biomarker and therapeutic target for overcoming cisplatin resistance in HNSCC.